An Open-Label Phase 1 Study to Determine the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ-42756493 to Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2016
At a glance
- Drugs Erdafitinib (Primary)
- Indications Cancer; Liver cancer; Lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 30 Sep 2016 Status changed from recruiting to completed.
- 12 May 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016.
- 12 May 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Jul 2016.